- Home
- IDA vs RYTM Comparison
IDA vs RYTM Comparison
Compare IDA & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IDA | RYTM |
|---|---|---|
| Founded | 1915 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 6.4B |
| IPO Year | 1998 | 2017 |
Fundamental Metrics
Financial Performance| Metric | IDA | RYTM |
|---|---|---|
| Price | $141.92 | $86.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $139.57 | $129.93 |
| AVG Volume (30 Days) | 403.1K | ★ 709.0K |
| Earning Date | 05-22-2026 | 05-25-2026 |
| Dividend Yield | ★ 2.50% | N/A |
| EPS Growth | 7.27 | ★ 28.34 |
| EPS | ★ 5.90 | N/A |
| Revenue | ★ $1,746,972,000.00 | N/A |
| Revenue This Year | $10.87 | $57.46 |
| Revenue Next Year | $12.99 | $85.60 |
| P/E Ratio | $23.91 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $109.30 | $45.91 |
| 52 Week High | $145.94 | $122.20 |
Technical Indicators
Market Signals| Indicator | IDA | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 37.19 |
| Support Level | $138.41 | $85.59 |
| Resistance Level | $145.37 | $96.92 |
| Average True Range (ATR) | 2.58 | 5.11 |
| MACD | -0.62 | -0.45 |
| Stochastic Oscillator | 45.67 | 21.76 |
Price Performance
Historical ComparisonAbout IDA IDACORP Inc.
Idacorp Inc is a holding company that, through its subsidiaries, acts as an electric utility engaged in the generation, transmission, distribution, sale, and purchase of electric energy and capacity. The company's only reportable segment is utility operations. The utility operations segment's primary source of revenue is the regulated operations of Idaho Power. The company serves commercial and industrial customers, which are involved in food processing, electronics and general manufacturing, agriculture, health care, government, education, and information technology.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.